Precision medicine has advanced significantly over the past decade, driven by breakthroughs in chemical, hardware, software, and especially cloud computing technologies. 18 March 2025
MeiraGTx has entered into a strategic partnership with artificial intelligence firm Hologen to accelerate the Phase III development of AAV-GAD, a gene therapy for Parkinson’s disease. 13 March 2025
Insilico Medicine has raised $110 million in a series E funding round to drive the development of its artificial intelligence-powered drug candidates, including its leading drug for idiopathic pulmonary fibrosis (IPF). 13 March 2025
Germany’s Boehringer Ingelheim has launched the One Medicine Platform, a new system designed to streamline drug development, following the implementation of Veeva Systems' Development Cloud. 12 March 2025
Nona Biosciences has introduced Hu-mAtrIx, an AI-assisted drug discovery platform designed to accelerate the identification and development of antibody-based therapies. 7 March 2025
The new US President has repealed an executive order from October 2023, signed by the Biden administration, that sought to establish rigorous safeguards for artificial intelligence (AI) development. 22 February 2025
US biopharma Incyte and privately-held AI-focused biotech Genesis Therapeutics have entered into a strategic collaboration focused on the research, discovery and development of novel small molecule medicines. 21 February 2025
French pharmaceutical company Servier and Google Cloud have announced an expanded five-year partnership aimed at leveraging artificial intelligence (AI) and generative AI to accelerate drug research and development. 16 January 2025
A collection of some of the largest US health systems, in collaboration with the Regeneron Genetics Center, have announced the launch of the Truveta Genome Project. 16 January 2025
Privately-held Italian drugmaker Menarini and its oncology-focused subsidiary Stemline Therapeutics have entered into a licensing deal with AI-driven biotech Insilico Medicines. 15 January 2025
Dyno Therapeutics, a privately-held US genetic technologies company applying AI to enable in vivo gene delivery, has announced that Roche has exercised its option to license a novel capsid for use in a gene therapy program for an undisclosed neurological disease indication. 13 January 2025
Belgian biopharmaceutical company UCB has entered into a license agreement with Ailux Biologics, the biologics discovery division of XtalPi, to leverage its AI platform. 9 January 2025
Insilico Medicine, a biotechnology firm specializing in artificial intelligence-powered drug discovery, has raised over $100 million in a series E funding round. 8 January 2025
The market for artificial intelligence (AI) in cancer care is projected to grow from $2.2 billion in 2024 to $6.3 billion by 2029, reflecting a growth rate of 23.1%, according to a recent study by BCC Research. 31 December 2024
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 20 December 2024
Shanghai-based Fangzhou, has entered into a strategic partnership with the Chinese business of Bristol Myers Squibb China, with the goal of enhancing digital platforms for chronic disease management. 19 December 2024
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
The Pan American Health Organization (PAHO) and non-profit PATH have published a report detailing the opportunities to improve vaccine programs through effective data use. 3 April 2019
US biotech major Celgene has become the latest drugmaker to team up with Exscientia, a privately-owned UK-based company that uses artificial intelligence (AI) in drug discovery. 21 March 2019
Japanese drugmaker Ono Pharmaceutical has signed a drug discovery research collaboration with twoXAR, a USA-based artificial intelligence (AI)-driven biopharmaceutical company, to jointly discover and develop novel, efficacious treatments to address unmet medical needs in a specific neurological disease. 19 March 2019
PureTech Health today announced that its independent affiliate Akili has entered into a strategic partnership with Japan’s Shionogi for the commercialization of two of Akili’s digital medicine product candidates. 7 March 2019
Adhera Therapeutics and Alyvant, yesterday announced a digital co-promotion agreement for Prestalia (perindopril arginine and amlodipine) therapy for the treatment of hypertension. 5 March 2019
Sanofi, UCB and leading US insurer BlueCross BlueShield are among the new strategic shareholders in Aetion, a tech company with a real-world analytics and evidence platform to engage in value-based care. 5 February 2019
Today, the first patients in the European Union can use digital prescriptions issued by their home doctor when visiting a pharmacy in another EU country. 21 January 2019
Swiss pharma giant Novartis (NOVN: VX) is to work with the University of Oxford’s Big Data Institute (BDI) to improve drug research and development using artificial intelligence (AI). 18 January 2019
US Food and Drug Administration Commissioner Scott Gottlieb has provided an update on the agency’s new actions under the Digital Health Precertification (Pre-Cert) Program. 8 January 2019
Japanese drugmaker Otsuka Pharmaceutical has become the latest pharma company to show faith in a US firm that develops software to address unmet medical need. 4 January 2019
Does the way artificial intelligence is used in pharma need to be reimagined? Irina Efimenko, chief executive of Russian analytics experts Semantic Hub, and Mike Samsonov, chief medical officer of R-Pharm, consider this question in an Expert View piece. 20 December 2018
Danish diabetes company Novo Nordisk has signed a research collaboration with e-therapeutics, a UK-based company with a computer-based drug discovery platform. 10 December 2018
A new pharma-partnered project has been set up to build a large-scale, federated network of data sources standardized to a common model. 23 November 2018
For the era of personalized therapies to truly arrive, industry observers often express the view that pharma will have to improve its understanding not just of biology and medicines, but also of certain new technologies that are likely to determine companies’ future way of working. 30 October 2018
Russia’s arrival as a major player in the digitalization of healthcare was abundantly clear at a Moscow event held to celebrate and stimulate advances in the sector. 25 October 2018